share_log

Allarity Therapeutics | 8-K: Current report

Allarity Therapeutics | 8-K: Current report

Allarity Therapeutics | 8-K:重大事件
美股SEC公告 ·  10/04 20:04

Moomoo AI 已提取核心訊息

Allarity Therapeutics, Inc. (NASDAQ: ALLR), a clinical-stage biopharmaceutical company, announced the appointment of Dr. Jeremy R. Graff as President and Chief Development Officer effective September 30, 2024. Dr. Graff, with over 25 years of experience in the biotech and pharmaceutical industry, has held various C-level and senior executive positions and has a strong background in the development of targeted cancer therapies. Prior to joining Allarity, he served as a consultant to the company and held roles at IMV, Inc., HiberCell, and Biothera Pharmaceuticals, Inc. He also worked at Eli Lilly for nearly 17 years. Dr. Graff's appointment is part of a strategic move to strengthen the company's leadership as it advances its clinical development programs, particularly the stenoparib PARP inhibitor program. Alongside Dr. Graff's appointment, Allarity has also brought on Dr. Jose Iglesias as Consultant Chief Medical Officer and Jesper Høiland as Strategic Advisor. The company is focused on the development of stenoparib using its Drug Response Predictor (DRP®) companion diagnostic for patient selection in ongoing clinical trials.
Allarity Therapeutics, Inc. (NASDAQ: ALLR), a clinical-stage biopharmaceutical company, announced the appointment of Dr. Jeremy R. Graff as President and Chief Development Officer effective September 30, 2024. Dr. Graff, with over 25 years of experience in the biotech and pharmaceutical industry, has held various C-level and senior executive positions and has a strong background in the development of targeted cancer therapies. Prior to joining Allarity, he served as a consultant to the company and held roles at IMV, Inc., HiberCell, and Biothera Pharmaceuticals, Inc. He also worked at Eli Lilly for nearly 17 years. Dr. Graff's appointment is part of a strategic move to strengthen the company's leadership as it advances its clinical development programs, particularly the stenoparib PARP inhibitor program. Alongside Dr. Graff's appointment, Allarity has also brought on Dr. Jose Iglesias as Consultant Chief Medical Officer and Jesper Høiland as Strategic Advisor. The company is focused on the development of stenoparib using its Drug Response Predictor (DRP®) companion diagnostic for patient selection in ongoing clinical trials.
Allarity Therapeutics,Inc.(納斯達克:ALLR)是一家臨床階段的生物藥品公司,宣佈任命Jeremy R. Graff博士爲總裁兼首席開發官,任期自2024年9月30日起生效。Graff博士在生物技術和藥品行業擁有超過25年的經驗,在開發靶向癌症療法方面擁有堅實背景,曾擔任各種C級別和高級執行職位。在加入Allarity之前,他曾擔任該公司顧問,並在IMV、HiberCell和Biothera Pharmaceuticals等公司擔任職位。他還在Eli Lilly工作了近17年。Graff博士的任命是公司加強領導團隊的戰略舉措的一部分,以推動其臨床開發計劃,特別是ste...展開全部
Allarity Therapeutics,Inc.(納斯達克:ALLR)是一家臨床階段的生物藥品公司,宣佈任命Jeremy R. Graff博士爲總裁兼首席開發官,任期自2024年9月30日起生效。Graff博士在生物技術和藥品行業擁有超過25年的經驗,在開發靶向癌症療法方面擁有堅實背景,曾擔任各種C級別和高級執行職位。在加入Allarity之前,他曾擔任該公司顧問,並在IMV、HiberCell和Biothera Pharmaceuticals等公司擔任職位。他還在Eli Lilly工作了近17年。Graff博士的任命是公司加強領導團隊的戰略舉措的一部分,以推動其臨床開發計劃,特別是stenoparib PARP抑制劑計劃。除了任命Graff博士外,Allarity還聘請了Jose Iglesias博士擔任顧問首席醫療官和Jesper Høiland擔任戰略顧問。該公司專注於利用其藥物反應預測器(DRP®)伴隨診斷,開發stenoparib用於正在進行的臨床試驗中的患者選擇。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息